Chief financial officer

DGAP-News: Carbios strengthens Executive Committee with the appointment of Pascal Bricout as Chief Strategy & Financial Officer

Retrieved on: 
Thursday, September 1, 2022
Nature, Enzyme, ISIN, Partnership, PET, Indorama Ventures, Technology, Chief financial officer, Polymer, Solution, Corporate social responsibility, Heart, Policy, PricewaterhouseCoopers, Plastic, Social responsibility, PUMA, Goal, Michelin, PLA, PepsiCo, Company, Textile, Growth, Salomon, Management, SME, Carbios

Clermont-Ferrand, France, September 1st 2022 (06:45 AM CEST), Carbios (EuronextGrowthParis: ALCRB), a pioneer in the development of enzymatic solutions dedicated to the end-of-life of plastic and textile polymers, today announced the appointment of Pascal Bricout as Chief Strategy and Financial Officer and a member of the Companys Executive Committee.

Key Points: 
  • Clermont-Ferrand, France, September 1st 2022 (06:45 AM CEST), Carbios (EuronextGrowthParis: ALCRB), a pioneer in the development of enzymatic solutions dedicated to the end-of-life of plastic and textile polymers, today announced the appointment of Pascal Bricout as Chief Strategy and Financial Officer and a member of the Companys Executive Committee.
  • Carbios CEO Emmanuel Ladent said: We are delighted to welcome Pascal Bricout to Carbios Executive Committee.
  • Prior to joining Carbios, Mr. Bricout served as Chief Financial Officer for Michelin in Asia, which is a major area of growth and development for the company.
  • Mr. Bricout, Carbios Chief Strategy & Financial Officer noted: I am thrilled to be joining Carbios and proud to take part in this concrete, meaningful advance toward circular economy.

Nuo Therapeutics Provides Corporate and Business Update

Retrieved on: 
Tuesday, August 30, 2022
Security (finance), Chief financial officer, Centers for Medicare & Medicaid Services, Sumathi Best Television Current Reporting Award, PRP, Sale, California Pacific Medical Center, SEC, U.S. Securities and Exchange Commission, Mouth ulcer, GLOBE, Medicare, Prevalence, FDA, Company, Population, Diabetes, NCD, OTCQB, Patient, Nature, Financial services, Pharmaceutical industry, Risk management, Nuo, Infineon AURIX

HOUSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo” or the “Company”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced today an initial corporate and business update since re-establishing fully available commercial operations in the second quarter of this year.

Key Points: 
  • This investment will allow Nuo to deliver effective clinical outcomes in the treatment of chronic wounds, while substantially advancing the business opportunity and positioning Nuo for future success.
  • While being focused on business execution presently, Nuo believes that an uplisting to a national securities exchange will be a viable option at the appropriate time.
  • Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape.
  • The Company expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

China Online Education Group Announces Second Quarter 2022 Results

Retrieved on: 
Tuesday, August 30, 2022
Online, ADS, CSE, Chief financial officer, Sustainable development, Sale, Director, Novo Nordisk, Central University, Board, IPO, Beijing City International School, Student, Central University of Finance and Economics, Economics, Company, International school, Growth, Marketing, Warehouse, Bank, Tutoring, Video game, Holding company, Management, Finance, Northeastern University, Shenyang China International Horticultural Exposition, Google

"In the second quarter of 2022, we successfully completed the divesture of our China mainland business and will solely focus on overseas business going forward.

Key Points: 
  • "In the second quarter of 2022, we successfully completed the divesture of our China mainland business and will solely focus on overseas business going forward.
  • Furthermore, to reflect our overseas focus, we will hold an annual general meeting on September 30th to vote on the proposal of changing our legal name from China Online Education Group to 51Talk Online Education Group."
  • The number of active students with attended lesson consumption of continuing operation was 14,900 in the second quarter of 2022.
  • Non-GAAP basic and diluted net loss per ADS attributable to ordinary shareholders for the second quarter of 2022 was US$0.67.

Babylon Appoints David Humphreys as Chief Financial Officer

Retrieved on: 
Tuesday, August 23, 2022
Apps, Applications, Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Other Health, Managed Care, Health, General Health, COVID-19, AI, CEO, Chief financial officer, NYSE, Telehealth, Time, Solution, PCAOB, Contract, Board, ACO, PricewaterhouseCoopers, IPO, International Accounting Standards Committee, Forward-looking statement, SEC, Infection, NHS, CFO, International Accounting Standards Board, Compliance, Silicon, Failure, Founder, Uncertainty, Risk, CPA, Growth, Record, Private Securities Litigation Reform Act, Audit, Management, Risk management, Healthcare, Kinnevik AB, Facebook

Babylon Holdings Limited (NYSE:BBLN) (Babylon or the Company), one of the worlds fastest growing digital healthcare companies, announces that David Humphreys will be appointed as the Companys new Chief Financial Officer.

Key Points: 
  • Babylon Holdings Limited (NYSE:BBLN) (Babylon or the Company), one of the worlds fastest growing digital healthcare companies, announces that David Humphreys will be appointed as the Companys new Chief Financial Officer.
  • Current Chief Financial Officer, Charlie Steel, will leave his position to pursue another opportunity.
  • Mr. Steel will remain at Babylon for a period to ensure the effective transition of his responsibilities to Mr. Humphreys.
  • We also heartily welcome David Humphreys as the new Babylon CFO.

Leading Brazilian Environmental and Industrial Solutions Provider Ambipar Response to Become Publicly Traded on NYSE via SPAC Merger with HPX Corp.

Retrieved on: 
Wednesday, July 6, 2022
Professional Services, Finance, Constellation, Slate, HPX, F-4, Register, Consultant, Growth, Industry, Suite, Mining, Simpson Thacher & Bartlett, Chief financial officer, BRT, Business, Securities Exchange Act of 1934, Reg, CRIMINAL, EBITDA, Prospectus, Skadden, Person, Proxy, THE, NYSE, SEC, IPO, Forward-looking statement, Section 14 of the Canadian Charter of Rights and Freedoms, Acquisition, Probability, BRL, BofA Securities, Private Securities Litigation Reform Act, Board, XP, Bank, USD, LLP, Sale, U.S. Securities and Exchange Commission, Form, PIPE, CFO, Business architecture, Registration statement, Environment, Shearman & Sterling, Renewable energy, Security (finance), Financial adviser, Risk management

The opportunity to partner with Ambipar Response perfectly fits the investment criteria that we defined in our IPO in 2020.

Key Points: 
  • The opportunity to partner with Ambipar Response perfectly fits the investment criteria that we defined in our IPO in 2020.
  • Ambipar Response is an industry leader in Brazil, with an extensive runway to continue to consolidate the fragmented environmental services industry worldwide.
  • Upon completion of the Business Combination, Ambipar Group is expected to hold at least a majority of the voting rights in Ambipar Response.
  • Ambipar Response is a leading environmental solutions service provider in Brazil with a global presence, with expected 2022 net revenue of approximately R$1.7 billion.

Kairos Ventures Closes Third Fund at $58 Million

Retrieved on: 
Monday, June 13, 2022
Science, Time, EfTEN Real Estate Fund III, Research, III, Kairos, Disease, Female, Ecosystem, VTOL, Investment, Growth, Chief financial officer, Nobel Prize, Climate change, Cancer, University, Pharmaceutical industry

LOS ANGELES, June 13, 2022 /PRNewswire/ -- Kairos Ventures, an early stage venture capital firm investing in physical and life sciences, announced the close of its third fund ("Fund III"), with capital commitments of $58 million.

Key Points: 
  • LOS ANGELES, June 13, 2022 /PRNewswire/ -- Kairos Ventures, an early stage venture capital firm investing in physical and life sciences, announced the close of its third fund ("Fund III"), with capital commitments of $58 million.
  • "Our investment strategy at Kairos is driven by the belief that backing world class scientists can have a significant positive impact on the world," said Jim Demetriades, Founder and Chief Executive Officer of Kairos Ventures.
  • Fund III has made 27 investments in companies that are disrupting their respective industries and establishing first-of-its-kind offerings and impact.
  • Kairos Ventures is a venture capital firm based in Los Angeles, California.

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Retrieved on: 
Wednesday, June 1, 2022
Axiom Space, Company, Adenosine deaminase, Doctor of Philosophy, COVID-19, Supervisory board, University of Nijmegen (1655–80), U.S. Securities and Exchange Commission, Alnylam Pharmaceuticals, Intellectual property, Cancer, Forward-looking statement, CEO, MyTomorrows, Mass meeting, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, General counsel, Corporation, University, RNA, Security (finance), ProQR, Shareholder, Patient, Chief financial officer, Lawyer, GE Capital, AGM, Lists of diseases, Janssen Vaccines, Mutation, Leadership, Research, Annual report, Nasdaq, Therapy, GLOBE, ADAR, Risk, Corporate development, De Boer, Safety, Management, Pharmaceutical industry, Renewable energy

ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.

Key Points: 
  • ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.
  • Mr. Beukema is also nominated to join the Management Board, subject to approval by shareholders at the AGM.
  • Most recently, he has been General Counsel & Chief Corporate Development at Frame Cancer Therapeutics.
  • He is the scientific co-founder of ProQR and previously served as ProQRs Chief Innovation Officer from 2014 to 2022.

On Elects Dennis Durkin as a New Independent Member of the Board of Directors

Retrieved on: 
Wednesday, May 25, 2022
Fashion, Retail, Sports, Running, Other Retail, General Sports, Alex, Company, Xbox network, U.S. Securities and Exchange Commission, Running, Microsoft, Activision Blizzard, Director, Government, Board of directors, ATVI, Audit committee, Xbox, Financial Instruments and Exchange Act, Chief financial officer, Retirement, Harvard University, Board, Human, Amy Banse, Sensation, Securities Exchange Act of 1934, Corporation, Entrepreneurship, CFO, NYSE, Dartmouth College, Audit, Management, Rule

Swiss performance sports brand On (NYSE: ONON) announced today the election of Dennis Durkin as additional independent member of the Board of Directors.

Key Points: 
  • Swiss performance sports brand On (NYSE: ONON) announced today the election of Dennis Durkin as additional independent member of the Board of Directors.
  • Following the recent appointment of Amy Banse as an On Board member, we continue the journey of bringing highly experienced individuals with independent and diverse viewpoints to the On Board of Directors.
  • Mr. Durkin has served as a board observer to the On Board of Directors from September 2021 through May 2022.
  • Following the appointment of Dennis Durkin as a member and the Chairman of the Audit Committee, Caspar Coppetti resigned from the Audit Committee.

Avenge Bio Presents Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Thursday, May 19, 2022
Cancer, Immunotherapy, Toxicity, Neoplasm, Primate, Rice University, 2021 Essex County Council election, Multimedia, Society, Chief financial officer, Gene, IND, Mesothelioma, Biotechnology, Technology, Malignancy, Ovarian cancer, Lung, MPM, Cell, The Company, Vaccine, Mouse

"In addition, we continue to build a robust data set for AVB-001, a novel immunotherapy, in malignant pleural mesothelioma.

Key Points: 
  • "In addition, we continue to build a robust data set for AVB-001, a novel immunotherapy, in malignant pleural mesothelioma.
  • All of our development programs leverage Avenge's LOCOcyte platform to deliver proprietary encapsulated engineered human cells to the local tumor environment."
  • Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte platform.
  • Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers.

Jiayin Group Inc. Announces Changes in Management

Retrieved on: 
Monday, May 9, 2022
Form 20-F, Forward-looking statement, Business, University, Senior, U.S. Securities and Exchange Commission, NASDAQ, GLOBE, Algorithm, Company, Engineering, Annual report, Microsoft, Shanghai Jiao Tong University, Deloitte, Industry, Shenyin Shu, Nasdaq, Private Securities Litigation Reform Act, MBA, Chief financial officer, SEC, Terminology, New Senior Investment Group, Risk assessment, Management, Security (finance), Nomura, PRC

SHANGHAI, China, May 09, 2022 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (Jiayin or the Company) (NASDAQ: JFIN), a leading fintech platform in China, today announced Mr. Chunlin Fan has rejoined the Company as Chief Financial Officer, effective from May 5, 2022.

Key Points: 
  • SHANGHAI, China, May 09, 2022 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (Jiayin or the Company) (NASDAQ: JFIN), a leading fintech platform in China, today announced Mr. Chunlin Fan has rejoined the Company as Chief Financial Officer, effective from May 5, 2022.
  • Fan previously served as the Companys Chief Financial Officer from January 2016 to January 2021.
  • Fan worked as the Chief Financial Officer of LinkDoc Techology Limited from January 2021 to March 2022.
  • Jiayin Group Inc. is a leading fintech platform in China committed to facilitating effective, transparent, secure and fast connections between underserved individual borrowers and financial institutions.